- Home
- NEWT vs LFCR Comparison
NEWT vs LFCR Comparison
Compare NEWT & LFCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEWT
- LFCR
- Stock Information
- Founded
- NEWT 1998
- LFCR 1986
- Country
- NEWT United States
- LFCR United States
- Employees
- NEWT N/A
- LFCR N/A
- Industry
- NEWT Major Banks
- LFCR Biotechnology: Pharmaceutical Preparations
- Sector
- NEWT Finance
- LFCR Health Care
- Exchange
- NEWT Nasdaq
- LFCR Nasdaq
- Market Cap
- NEWT 316.7M
- LFCR 288.0M
- IPO Year
- NEWT N/A
- LFCR N/A
- Fundamental
- Price
- NEWT $10.74
- LFCR $6.85
- Analyst Decision
- NEWT Hold
- LFCR Buy
- Analyst Count
- NEWT 4
- LFCR 4
- Target Price
- NEWT $13.25
- LFCR $8.00
- AVG Volume (30 Days)
- NEWT 217.3K
- LFCR 216.3K
- Earning Date
- NEWT 10-29-2025
- LFCR 10-03-2025
- Dividend Yield
- NEWT 7.08%
- LFCR N/A
- EPS Growth
- NEWT 21.23
- LFCR N/A
- EPS
- NEWT 2.01
- LFCR N/A
- Revenue
- NEWT $364,004,000.00
- LFCR $128,867,000.00
- Revenue This Year
- NEWT N/A
- LFCR $4.72
- Revenue Next Year
- NEWT $12.40
- LFCR $10.97
- P/E Ratio
- NEWT $5.33
- LFCR N/A
- Revenue Growth
- NEWT 20.91
- LFCR 0.47
- 52 Week Low
- NEWT $9.12
- LFCR $4.76
- 52 Week High
- NEWT $15.49
- LFCR $8.85
- Technical
- Relative Strength Index (RSI)
- NEWT 39.77
- LFCR 47.62
- Support Level
- NEWT $10.30
- LFCR $6.44
- Resistance Level
- NEWT $11.11
- LFCR $6.94
- Average True Range (ATR)
- NEWT 0.32
- LFCR 0.26
- MACD
- NEWT -0.00
- LFCR 0.03
- Stochastic Oscillator
- NEWT 43.24
- LFCR 66.03
About NEWT NewtekOne Inc.
NewtekOne Inc is a financial holding company engaged in providing financial solutions to its Client Base. It is an internally managed non-diversified closed-end management investment company. It has four reportable segments Banking, Alternative Lending, Technology, NSBF, and Payments.
About LFCR Lifecore Biomedical Inc.
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that provides services in the development, fill, and finish of complex sterile injectable pharmaceutical products in syringes, vials, and cartridges. The group recognizes revenue in two different product categories, CDMO and HA manufacturing.